Es gibt sehr wenige neue Moleküle, sehr wenige neue Ideen und beinahe nichts, das hoffen ließe, die medikamentöse Behandlung psychischer Erkrankungen zu transformieren. Aufgrund mangelnder Erfolge ziehen sich mehrere Pharmaunternehmen aus dem Geschäft zurück.
Broad Review of FDA Trials Suggests Antidepressants Only Marginally Better than Placebo
„We found that out of the 4041 patients initially started on the SSRI [selective serotonin reuptake inhibitor] citalopram in the STAR*D study, and after 4 trials, only 108 patients had a remission and did not either have a relapse and/or dropped out by the end of 12 months of continuing care,“ lead study author Ed Pigott, PhD, a psychologist with NeuroAdvantage LLC in Clarksville, Maryland.
„In other words, if you’re trying to look at sustained benefit, you’re only looking at 2.7%, which is a pretty jaw-dropping number,“ added Dr. Pigott.